Assessment of genetically modified maize DP23211 for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐NL‐2019‐163)

Abstract

Genetically modified maize DP23211 was developed to confer control of certain coleopteran pests and tolerance to glufosinate‐containing herbicide. These properties were achieved by introducing the pmi, mo‐pat, ipd072Aa and DvSSJ1 expression cassettes. The molecular characterisation data and bioinformatic analyses do not identify issues requiring food/feed safety assessment. None of the identified differences in the agronomic/phenotypic and compositional characteristics tested between maize DP23211 and its conventional counterpart needs further assessment, except for those in levels of histidine, phenylalanine, magnesium, phosphorus and folic acid in grain, which do not raise safety and nutritional concerns. The GMO Panel does not identify safety concerns regarding the toxicity and allergenicity of the IPD072Aa, PAT and PMI proteins and the DvSSJ1 dsRNA and derived siRNAs newly expressed in maize DP23211, and finds no evidence that the genetic modification impacts the overall safety of maize DP23211. In the context of this application, the consumption of food and feed from maize DP23211 does not represent a nutritional concern in humans and animals. Therefore, no post‐market monitoring of food/feed is considered necessary. In the case of accidental release of viable maize DP23211 grains into the environment, this would not raise environmental safety concerns. The post‐market environmental monitoring plan and reporting intervals are in line with the intended uses of maize DP23211. The GMO Panel concludes that maize DP23211 is as safe as its conventional counterpart and the tested non‐GM reference varieties with respect to potential effects on human and animal health and the environment.

Assessment of genetically modified maize DP202216 for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐NL‐2019‐159)

“…The effects of temperature and pH on PAT protein have been previously evaluated by the GMO Panel (EFSA, 2005 , 2007 ; EFSA GMO Panel, 2018c , 2024a , 2024b ). In relation to the ZMM28 protein, the deduced amino acid sequence as defined by the zmm28 gene introduced in maize DP202216 is identical to the endogenous ZMM28 protein present in the GM plant (see Section 3.3.3.1 ) and no studies were provided by the applicant.…”

“…In vitro protein degradation studies on PAT protein have been previously evaluated by the EFSA GMO Panel (EFSA, 2005 , 2007 ; EFSA GMO Panel, 2018c , 2024a , 2024b ). In relation to the ZMM28 protein, no studies were provided by the applicant.…”

“…The PAT protein was previously assessed by the GMO Panel in the context of other applications (EFSA, 2005 , 2007 ; EFSA GMO Panel, 2018 , 2024a , 2024b ) and no safety concerns for humans and animals (i.e. farmed and companion animals) were identified.…”

Assessment of genetically modified maize DP910521 (application GMFF‐2021‐2473)

“…The PAT and PMI proteins have been previously assessed by the GMO Panel and no safety concerns for humans and animals (i.e. farmed and companion animals) were identified (EFSA GMO Panel, 2012 , 2017b , 2024 ).…”

“…The effects of temperature and pH on PAT and PMI proteins as expressed in maize DP910521 were previously assessed by the GMO Panel (EFSA GMO Panel, 2012 , 2017b , 2024 ). The applicant provided studies on the Cry1B.34 protein as expressed in maize DP910521.…”